Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - exemestane 25 mg - film-coated tablet - 25 mg - exemestane 25 mg - exemestane

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - exemestane 25 mg - film-coated tablet - 25 mg - exemestane 25 mg - exemestane

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - exemestane -

Canada - English - Health Canada

teva canada limited - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Canada - English - Health Canada

apotex inc - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

helm ag - exemestane - coated tablets - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - exemestane - coated tablets - 25 milligram

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - exemestane - tablets film-coated - 25mg

United States - English - NLM (National Library of Medicine)

alvogen inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies ( 14.1 )] . exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies ( 14.2 )] . exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abo

United States - English - NLM (National Library of Medicine)

a-s medication solutions - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies ( 14.1 )] . exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies ( 14.2 )] . exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abo